May 3rd 2024
In this Pharmaceutical Executive video interview, Jesse Mendelsohn, senior vice president at Model N, talks about the influence of Medicare Part D drug price negotiations on manufacturer go-to-market strategies and decision-making, and the industry’s response to the wider dialogue on pricing transparency.
Drug Price Controls: “Red Meat for the Left” or Russian Roulette?
September 18th 2015Kaiser’s August healthcare poll results should put all on high alert given public sentiment and the rhetoric of the political season. Ed Schoonveld sounds the alarm and offers four initiatives to stall the surge towards government intercession on escalating prices.
Partnering in a Volume to Value Transformational Environment
March 12th 2015In the shift from volume to value as the underlying driver in health care, pharma has only scratched the surface of possibility for new and non-traditional arrangements with a broader variety of partners with healthcare interests, writes Cliff Kalb.